(6) The ongoing novel coronavirus outbreak reflects the pressing need for quick and effective vaccine and countermeasure development. (7) While the need for vaccines to address emerging epidemic threats is acute, markets to drive the necessary development of vaccines to address them—a complex and expensive undertaking—are very often critically absent. Also absent are mechanisms to ensure access to those vaccines by those who need them when they need them. (8) To address this global vulnerability and the deficit of political commitment, institutional capacity, and funding, in 2017, several countries and private partners launched the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI’s mission is to stimulate, finance, and coordinate development of vaccines for high-priority, epidemic-potential threats in cases where traditional markets do not exist or cannot create sufficient demand. (9) Through funding of partnerships, CEPI seeks to bring priority vaccines candidates through the end of phase II clinical trials, as well as support vaccine platforms that can be rapidly deployed against emerging pathogens. (10) CEPI has funded multiple partners to develop vaccine candidates against the novel coronavirus, responding to this urgent, global requirement. (11) Support for and participation in CEPI is an important part of the United States own health security and biodefense and is in the national interest, complementing the work of many Federal agencies and providing significant value through global partnership and burden-sharing. 191514. Authorization for united states participation (a) In general The United States is hereby authorized to participate in the Coalition for Epidemic Preparedness Innovations. (b) Privileges and immunities The Coalition for Epidemic Preparedness Innovations shall be considered a public international organization for purposes of section 1 of the International Organizations Immunities Act ( 22 U.S.C. 288 ). (c) Reports to congress Not later than 180 days after the date of the